12.03.2018 • News

Saudi Aramco Listing Delayed until 2019

Saudi Aramco Listing Delayed until 2019
Saudi Aramco Listing Delayed until 2019

An initial public offering (IPO) by Saudi Aramco is unlikely to take place before 2019 at the earliest, according to reports from London, where Prince Crown Prince Mohammed bin Salman recently held talks with the British government.

The oil and petrochemicals group had been planning to float 5% of the company’s shares, both at on the Saudi Tadawul and on an international exchange. The launch was expected to take place this year, but according to the business newspaper Financial Times (FT), the project will be delayed.

Aramco is the world’s biggest oil producer and one of the principal sources of wealth in the Kingdom, where, as observers point out, taxes only recently have been levied. Even though only 5% was planned to be floated, the launch was expected to be the biggest ever.

Financial advisers to the Saudi government are reportedly struggling to achieve the $2 trillion valuation targeted by the prince, while at the same time grappling with financial, legal and regulatory challenges stemming from opening up a company that for decades has been shrouded in secrecy, the FT said.

While Prince Mohammed is said to favor an ipo in New York – a trial balloon already has been launched by US President Donald Trump –Saudi officials on the whole are believed to be split, with Energy Minister Khalid Al Falih regarding London a better fit and others eyeing Hong Kong, where big cornerstone investors could be brought on board. 

Some commentators have suggested the listing might not go ahead at all, speculating that the stake could be sold to a sovereign wealth fund, possibly the Chinese.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read